Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency

• Main Authors: Tinh-Hai Collet (Author), Béatrice Dubern (Author), Jacek Mokrosinski (Author), Hillori Connors (Author), Julia M. Keogh (Author), Edson Mendes de Oliveira (Author), Elana Henning (Author), Christine Poitou-Bernert (Author), Jean-Michel Oppert (Author), Patrick Tounian (Author), Florence Marchelli (Author), Rohia Alili (Author), Johanne Le Beyec (Author), Dominique Pépin (Author), Jean-Marc Lacorte (Author), Andrew Gottesdiener (Author), Rebecca Bounds (Author), Shubh Sharma (Author), Cathy Folster (Author), Bart Henderson (Author), Stephen O'Rahilly (Author), Elizabeth Stoner (Author), Keith Gottesdiener (Author), Brandon L. Panaro (Author), Roger D. Cone (Author), Karine Clément (Author), I. Sadaf Farooqi (Author), Lex H.T. Van der Ploeg (Author)
• Format: Book
• Published: Elsevier, 2017-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objective: Pro-opiomelanocortin (POMC)-derived peptides act on neurons expressing the Melanocortin 4 receptor (MC4R) to reduce body weight. Setmelanotide is a highly potent MC4R agonist that leads to weight loss in diet-induced obese animals and in obese individuals with complete POMC deficiency. Wh...